Cogent Biosciences, Inc. Capital Expenditures Incurred but Not yet Paid
Cogent Biosciences, Inc. (COGT) reported Capital Expenditures Incurred but Not yet Paid of $81.00 thousand for the 6-month period ending 2018-06-30, per its 10-Q filed 2019-08-12.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2019-08-12
- Cogent Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2018-06-30 was -$27.00K.
- Cogent Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2018-03-31 was $108.00K.
- Cogent Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2017-12-31 was $60.00K.
- Cogent Biosciences, Inc. capital expenditures incurred but not yet paid for the quarter ending 2017-09-30 was -$55.00K.
- Cogent Biosciences, Inc. capital expenditures incurred but not yet paid for fiscal 2017 was $75.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2018-06-30 | -$27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $81.00K 10-Q · filed 2019-08-12 | $141.00K derived: sum of 3 quarters · filed 2019-08-12 | $86.00K derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $108.00K 10-Q · filed 2019-05-13 | $168.00K derived: sum of 2 quarters · filed 2019-05-13 | $113.00K derived: sum of 3 quarters · filed 2019-05-13 | |
| 2017-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | $5.00K derived: sum of 2 quarters · filed 2019-03-28 | $75.00K 10-K · filed 2019-03-28 | |
| 2017-09-30 | -$55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $15.00K 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $70.00K 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |